Journal of Experimental & Clinical Cancer Research · 2014 · 40 citations · 24 references
MedicineEndocrinologyOncologyEndocrine OncologyNeoplasiaNeuro-oncologyDopaminergic PharmacologyHormonal TherapyHormone-secreting TumorsPituitary DisordersPituitary HormonesPituitary TumorsClinical Significance AssessmentD2-like Dopamine ReceptorsDopamine D2-like ReceptorsDopamine Receptor AgonistsHistopathological SubtypesPituitary Tumor ImmunohistochemistryPituitary Tumor Prognostic MarkersWestern Blot Analysis
BACKGROUND: To study the expression of D2R, MGMT and VEGF for clinical significance in pituitary adenomas, and to predict the potential curative medical therapy of dopamine agonists, temozolomide and bevacizumab on pituitary adenomas. METHODS: Immunohistochemistry and western blot were performed to detect the expression of expression of D2R, MGMT and VEGF in pituitary adenoma tissue samples. The ratio of high expression of D2R, MGMT or VEGF in different subtypes of PA was compared by the use of chi-squared tests. The relationships between D2R, MGMT and VEGF expression were assessed by the Spearman rank correlation test. The association between their expression and clinical parameters was analyzed using a chi-squared test, or Fisher's exact probability test when appropriate. RESULTS: The data showed that in 197 different histological subtypes of pituitary adenomas (PAs), 64.9% of them were D2R high expression, 86.3% were MGMT low expression and 58.9% were VEGF high expression. D2R high expression existed more frequently in PRL- and GH- secreting PAs. MGMT low expression existed in all PA subtypes. VEGF high expression existed more frequently in PRL, ACTH, FSH secreting and non-functioning PAs. The data of western blot also support the results. Spearman's rank correlation analysis showed that expression of MGMT was positively associated with D2R (r = 0.154, P = 0.031) and VEGF (r = 0.161, P = 0.024) in PAs, but no correlation was showed between D2R and VEGF expression (r = -0.025, P = 0.725 > 0.05). The association between their expression and clinical parameters was analyzed using a chi-squared test, or Fisher's exact probability test when appropriate, but the result showed no significant association. CONCLUSIONS: PRL-and GH-secreting PAs exist high expression of D2R, responding to dopamine agonists; Most PAs exist low expression of MGMT and high expression of VEGF, TMZ or bevacizumab treatment could be applied under the premise of indications.
24
Pituitary Adenomas with Invasion of the Cavernous Sinus Space
Engelbert Knosp, Erich Steiner, K. Kitz et al. · Neurosurgery · 1993 · 1.2K citations
Olivier Chinot, Maryline Barrié, S. Fuentès et al. · Journal of Clinical Oncology · 2007 · 203 citations · Full text
Long-term response of pituitary carcinoma to temozolomide
Camilo E. Fadul, Andrew L. Kominsky, Louise P. Meyer et al. · Journal of neurosurgery · 2006 · 165 citations
Medicine, Oncology, Chemotherapy +13